Targeted Oncology
Targeted Oncology
Targeted Oncology
  • Question 1
  • Question 2
  • Question 3
  • Question 4
  • Question 5

1. When presented with a patient showing symptoms consistent with Castleman Disease, what other diseases need to be ruled out?

NEXT

2. Which of these tests are uninformative for differential diagnosis of MCD.

NEXT

3. Which are not characteristic of TAFRO syndrome as defined in patients with MCD?

NEXT

4. Which features, as determined by lymph node pathology, would not indicate that the patient may have the plasmacytic variant of MCD?

NEXT

5. Based on the FDA indication for siltuximab, what factors are considered when prescribing it?

SYLVANT® (siltuximab) is indicated for the treatment of patients with Multicentric Castleman`s Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Limitation of use: SYLVANT® was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT® did not bind to virally produced interleukin-6 (IL-6) in a nonclinical study.
Publications